Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
GreenLight Biosciences has appointed Dr. Barney Graham to its Human Health Scientific Advisory Board. Dr. Graham, an influential immunologist and former deputy director of the NIAID Vaccine Research Center, is recognized for his significant contributions to vaccine development, including the first COVID-19 vaccine.
His expertise in mRNA technology and vaccine design is expected to accelerate GreenLight's efforts toward improving global health. The company focuses on RNA-based solutions for human health and agriculture and is publicly traded under the ticker GRNA.
- Appointment of Dr. Barney Graham, a distinguished immunologist, to enhance scientific advisory capabilities.
- Dr. Graham's vast experience in vaccine development may accelerate mRNA-based advancements for global health.
- Concerns about continuity and experience gaps post-retirement of key personnel may arise.
Insights
Analyzing...
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant health, is proud to welcome Barney Graham, MD, PhD., to its Human Health Scientific Advisory Board.
The former deputy director of the NIAID Vaccine Research Center, Dr. Graham is an immunologist, virologist, and clinical trials physician with an extensive background in basic and translational research applied to vaccine development. He is best known for his research on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases.
“I look forward to working with GreenLight to advance affordable mRNA manufacturing options and improve global health equity,” said Dr. Graham.
Until his retirement last year, Dr. Graham was the chief of the Viral Pathogenesis Laboratory and Translational Science Core. He was named one of the world’s 100 most influential individuals and one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine. He was also recognized as the Federal Employee of the Year by the Partnership for Public Service.
Dr. Graham is an author on more than 500 scientific publications and a thought leader on emerging viral diseases and pandemic preparedness. He was involved in the advanced evaluation of vaccines and monoclonal antibodies for HIV, Ebola, and Chikungunya. He also developed novel vaccines for RSV, influenza, Zika, paramyxoviruses, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody to enter clinical testing and that subsequently achieved Emergency Use Authorization and licensure.
Dr. Graham obtained his MD from the University of Kansas School of Medicine, and his PhD in Microbiology & Immunology at Vanderbilt University School of Medicine, where he rose to the rank of Professor of Medicine with a joint appointment in the Department of Microbiology & Immunology. He is the recipient of numerous international awards and accolades for his contributions to research.
“We are delighted to have Dr. Graham join as an advisor,” said Amin Khan, GreenLight’s Human Health chief scientific officer. “Dr. Graham’s expertise in structure-based vaccine design, and translational medicine will help accelerate our progress in solving some of the world’s biggest problems by delivering on the full potential of RNA.”
About GreenLight Biosciences
GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit our website.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and GreenLight assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Thomas Crampton
SVP & Head of Corporate Affairs
GreenLight Biosciences
tcrampton@greenlightbio.com
+44 7826 995794
+1-914-202-2762
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fbc24d14-6e18-4097-8518-f40180b3ee38
FAQ
Who is Barney Graham and what is his role at GreenLight Biosciences?
What is the significance of Dr. Graham's appointment for GreenLight Biosciences?
What is GreenLight Biosciences focused on?
What is the ticker symbol for GreenLight Biosciences?
